Renal denervation for the treatment of drug-resistant hypertension has been studied extensively in the past few years. Although early trials reported dramatic reductions in blood pressure after renal denervation, later trials testing denervation against a sham procedure showed neutral results. In this Perspectives article, Gulati and colleagues suggest potential reasons why results from these early trials could not be replicated, and summarize the current available trial data, newly designed devices, and recommendations for future trial design.
- Rajiv Gulati
- Claire E. Raphael
- Bernard J. Gersh
